Table 5.
Adjuvant regimens administered
| Total (n=43) |
|
| N (%) | |
| Adjuvant treatment regimens | |
| Paclitaxel | 12 (27.9) |
| Doxorubicin+ifosfamide | 6 (14.0) |
| Gemcitabine+docetaxel | 6 (14.0) |
| Gemcitabine+docetaxel+doxorubicin+ifosfamide | 5 (11.6) |
| Doxorubicin | 3 (7.0) |
| Gemcitabine | 2 (4.7) |
| Cisplatin | 2 (4.6) |
| Docetaxel | 1 (2.3) |
| Ifosfamide | 1 (2.3) |
| Caelyx | 1 (2.3) |
| Epirubicine | 1 (2.3) |
| Temozolomide | 1 (2.3) |
| Vincristine+dacarbazine | 1 (2.3) |
| Vinorelbine | 1 (2.3) |